Associated Papers
Oncogenic driver mutations in lung cancer.
Luo SY et al.
Translational Respiratory Medicine, 2013
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H et al.
British Journal of Cancer, 2006
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Huang SF et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
Select a paper to view details